Cure My Disease

Don't miss your cure!

 Log in / Sign up

Combination therapy aims to boost blood cells in Hard-to-Treat MDS

NCT ID NCT06020833

Disease control Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This trial tests whether combining roxadustat with retinoic acid can help people with low-risk myelodysplastic syndromes (MDS) whose disease hasn't responded to initial treatment. The goal is to improve blood cell counts and reduce the need for transfusions. Participants will take both drugs orally for 8 weeks, and researchers will measure how many achieve complete or partial remission.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
roxadustat combined with retinoic acid
What this could lead to
If it works, this combination could offer a new treatment option for people with low-risk MDS who haven't responded to standard therapy, potentially reducing or eliminating the need for blood transfusions.
What could go wrong
This is an early-phase, single-arm trial with no control group, so results are preliminary. The combination may cause side effects or prove no more effective than existing options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Expected to start

Aug 2023

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Low-risk MDS unresponsive to first-line therapy Exclusion Criteria: * myelofibrosis * Severe heart and kidney function bu'quan

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myelodysplastic syndromes are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myelodysplastic syndromes

More trials for these conditions

Other studies related to the condition(s) this trial covers.